Molecular Models of the Lung Cancer Drug Osimertinib In Complex With Egfr (IMAGE)
Caption
Molecular models of the lung cancer drug osimertinib in complex with EGFR. On the left, osimertinib assumes a conformation that allows it to react with Cys797 leading to the effective inhibition of the enzyme and to cancer cell death. On the right, the presence within EGFR of a residue able to form additional interactions with osimertinib (as for the L718Q mutant form) prevents its reaction with Cys797 allowing EGFR to work and cancer cells to survive.
Credit
University of Bristol
Usage Restrictions
None
License
Licensed content